A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Summary
Third Opinion Trial Synopsis:
This study will give patients with multiple myeloma a new form of treatment called D-ClaPd. The patients will take this treatment until they either get worse or have bad side effects. The study will see if this new treatment is better than the old treatment for patients who have had a similar treatment before. The study hopes to see more patients get better with this new treatment.
This study will give patients with multiple myeloma a new form of treatment called D-ClaPd. The patients will take this treatment until they either get worse or have bad side effects. The study will see if this new treatment is better than the old treatment for patients who have had a similar treatment before. The study hopes to see more patients get better with this new treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.
This is a single-center, non-randomized, phase 2 study in which patients will receive daratumumab (subcutaneous, SC) in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity. This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of clarithromycin/pomalidomide/dexamethasone with daratumumab SC (D-ClaPd) will yield higher Very Good Partial Response (VGPR) rates in relapsed/refractory multiple myeloma patients than historical pomalidomide/dexamethasone treatment.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: